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PREVENTT: preoperative intravenous iron to
treat anaemia in major surgery: study
protocol for a randomised controlled trial
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Abstract
Background: Anaemia is common in patients undergoing major surgery. The current standard of care for
patients with low haemoglobin in the peri-operative period is blood transfusion. The presence of preoperative
anaemia is associated with an increased likelihood of the patient receiving peri-operative transfusion and worsened
outcomes following surgery, more post-operative complications, delayed recovery and greater length of hospital stay.
Intravenous iron, if applied in the preoperative setting, may correct anaemia by the time of surgery and reduce the
need for blood transfusion and improve outcomes.
Methods/Design: PREVENTT is a phase III double-blind randomised controlled trial that will compare the use
of intravenous ferric carboxymaltose (dose 1000 mg) with placebo 10–42 days before major open abdominal
surgery in 500 patients with anaemia (haemoglobin < 120 g/L). The primary outcome measure will be the need
for blood transfusion and secondary endpoints will include post-operative recovery, length of hospital stay,
health care utilisation and cost analysis.
Trial registration: ISRCTN67322816 – registered 9 October 2012.
ClinicalTrials.gov identifier: NCT01692418.
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Background
The World Health Organisation defines anaemia as insuf-
ficient red blood cell (RBC) mass to meet the body’s
physiological needs with a haemoglobin (Hb) concentra-
tion of < 130 g/L for men and < 120 g/L for non-pregnant
women [1]. Anaemia is associated with impaired physical
function, reduced quality of life, infection, increased pa-
tient morbidity and mortality [2]. Preoperative anaemia is
common, affecting 30–60 % of all patients undergoing
major elective surgery [3]. In the surgical setting anaemia
compounds the stress of operation; anaemia is an inde-
pendent risk factor for blood transfusion, in-patient com-
plications, delayed hospital discharge and poorer recovery
[4]. The causes for anaemia in this patient group are often
multifactorial and can be due to blood losses, nutritional
causes, functional iron deficiency associated with elevated
hepcidin (cancer and/or inflammatory disease – anaemia
of chronic disease (ACD)), or a combination of these [5].
Two main types of anaemia affect surgical patients, iron
deficiency anaemia (IDA) and ACD; the latter is more
common in chronically ill and hospitalised patients [6].
ACD can be difficult to diagnose, often being regarded
as a diagnosis of exclusion. A key feature of ACD is a
disruption of normal iron homeostasis initiated by a
cytokine-mediated immune response, such as in chronic
inflammatory disease, during infection or following sur-
gery [6, 7]. This inability to define ‘iron deficiency’ in
patients with anaemia before operation has meant that
most patients are not treated with iron therapy, and blood
transfusion in the peri-operative period remains the
standard of care [8].
The demand for blood components increases every
year. In 2008 to 2009 1.86 million units of blood were
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transfused in the UK at an overall cost of provision
to the NHS of £247.4 million. Although anaemia in-
creases the requirement for transfusion, blood trans-
fusion itself has been associated independently with a
worse patient outcome. Prospective observational studies
suggest that allogenic blood transfusion (ABT) increases
the risk of post-operative complications and longer hos-
pital stay [9, 10].
Intravenous (IV) iron is the standard of care for iron
supplementation in patients with iron deficiency an-
aemia in chronic renal failure [11]. Its use has widened
to routinely treat anaemia in patients with inflammatory
bowel disease [12], and cardiac disease [13]. The intro-
duction of new IV iron preparations that can be admi-
nistered as a single treatment of up to 1000 mg in a
relatively short (15 min) time without the need for a test
dose and with low risk of reactions, have facilitated small
trials within the fields of obstetric, gynaecological and
orthopaedic surgery. These studies have suggested that
IV iron may rapidly increase Hb levels before operation
and this may result in lower transfusion rates [14–20].
Two recent reviews called for a randomised controlled
trial (RCT) on the role of IV iron in surgery to prevent
blood transfusion [21, 22].
We aim to assess whether a single treatment dose of
IV ferric carboxymaltose (FCM) given to anaemic pa-
tients prior to major abdominal surgery would reduce
the need for blood transfusion in the peri-operative
period. Furthermore, this intervention may reduce post-
operative complications and overall prove cost-effective.
Methods/Design
Adult patients undergoing elective major open abdom-
inal surgery, defined as an operation of anticipated dur-
ation more than 1 h, will be eligible for screening. The
indication for operation may be for benign or malignant
disease.
To date, multiple studies have compared laparoscopic
to open surgery. Laparoscopic surgery is now routine
practice in many areas of surgery. Cochrane database
reviews suggest a benefit in reducing the need for blood
transfusion and reduced length of hospital stay [23–25].
In major abdominal surgery such as gastrectomy, colec-
tomy, nephrectomy or cystectomy and hysterectomy (for
malignant disease) open surgery remains the mainstay of
treatment. In the majority of open cases patients have
complex disease or require extensive surgery. Conse-
quently these patients have a higher event rate. In con-
trast, patients undergoing laparoscopic surgery may be
more selected; often for benign disease or in cases where
the surgery may be less extensive or technically easier.
In laparoscopic surgery the post-operative event rate
may be lower. Therefore, it was decided to exclude
laparoscopic surgery because of a need to increase the
overall number of participants in the study to allow
detection of a difference in endpoints.
Patients will be screened for inclusion into the trial at
a normal routine hospital attendance, such as outpatient
clinic visits or attendance for tests as part of their evalu-
ation for surgery (for example radiological tests or en-
doscopy). Those with screening Hb 90–120 g/L and able
to receive the study infusion 10 days to 42 days before
planned operation, will be eligible for randomisation.
Prior to inclusion, freely given written informed consent
must be obtained from all patients. Exclusion criteria
include patients undergoing laparoscopic surgery; body
weight under 50 kg; known history of acquired iron
overload; family history of haemochromatosis or thalas-
semia or transferrin saturation (TSAT) > 50 %; known
reason for anaemia (e.g. untreated vitamin B12 or folate
deficiency or haemoglobinopathy); treatment with ery-
thropoietin, IV iron therapy or blood transfusion in the
previous 12 weeks; known hypersensitivity to FCM or
its excipients; temperature > 37.5 °C or receiving non-
prophylactic antibiotics; chronic liver disease and/or
screening alanine transaminase (ALT) or aspartate trans-
aminase (AST) above 3 times the upper limit of the
normal range and those with severe asthma or severe
allergy.
The study protocol was approved by the National
Research Ethics Committee East of England – Welwyn,
5 November 2012, reference 12/EE/0445 EudraCt 2012-
002786-35. Further, the trial was registered in the US
clinical trials database NCT01692418.
Patient outcomes measures
The co-primary outcomes to be investigated are the risk
of blood transfusion (receiving any volume of 1 unit or
more than 1 unit of packed red cells or any other blood
component) or death, from randomisation until 30 days
following the index operation, and the blood transfusion
rate (including repeat transfusions) from randomisation
until 30 days following the index operation. Where more
than 1 unit of packed red cells or any other blood com-
ponent is intended to be received contiguously this is
regarded as a single blood transfusion (including single
unit transfusion practice when units are given contigu-
ously). The blood transfusion rate is defined as the num-
ber of blood transfusions divided by the total patient
time at risk.
Secondary outcome measures include the change in
haemoglobin levels from randomisation to day of index
operation, 8 weeks post index operation and 6 months
post index operation; total number of units of blood
or blood components cross matched; total number of
packed red cells and any blood components transfused
from randomisation to 30 days post index operation;
post-operative complications and the Post Operative
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Morbidity Survey (POMS) outcome at days 3, 5, 7 and
14 following the index operation [26].
Health-related Quality of Life (HRQoL) outcomes to
be assessed are change in the Multidimensional Fatigue
Inventory (MFI) questionnaire total score and European
Quality of Life: 5 Dimensions-5 Levels (EQ-5D-5 L)
questionnaire total score from baseline at day 10–8
weeks and 6 months post-operatively and change in
Single Question Outcome Measure (SQOM).
Health economics assessments will be health care
resource utilisation from baseline to 6 months post
surgery; calculated NHS and societal costs from baseline
to 6 months post surgery; Quality-adjusted Life Years
(QALYs) from baseline to 6 months post surgery; cost-
effectiveness measured in terms of the incremental
cost per percent reduction in patients receiving blood
transfusions; and incremental QALYs gained, using data
from baseline to 6 months post surgery.
The following safety and related efficacy outcomes will
be measured: any reaction or side effect from trial therapy;
any reaction or side effect from whole blood or blood
component, transfusion reaction; serious adverse events
(SAE) and suspected unexpected serious adverse reactions
(SUSARs); length of hospital stay; mortality at 8 weeks
and at 6 months post-operatively; readmission to hospital
for any reason within 8 weeks and within 6 months of the
index operation; rate of recurrent hospitalisations for any
reason; death; blood transfusion from randomisation to
8 weeks and to 6 months post-operatively; change in esti-
mated glomerular filtration rate (eGFR) during follow-up;
changes in vital signs and laboratory test data. See Fig. 1
for Assessments flow diagram.
Fig. 1 Assessments flow diagram
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Assessments
The ‘baseline assessments’, including laboratory tests
for the purposes of the PREVENTT trial, are the same
as those for routine clinical care in pre-assessment be-
fore major surgery. The screening and baseline period
will not exceed 4 weeks, including laboratory tests taken
within 4 weeks (full blood count (FBC), creatinine, urea
and electrolytes (UE), liver function tests (LFT), iron stud-
ies, estimated glomerular filtration rate eGFR, C-reactive
protein (CRP), thyroid function tests (TFT), vitamin B12
and folate); documentation of past medical history, vital
signs (blood pressure, pulse rate, body weight, height,
temperature. Additional blood samples will be taken for
central laboratory analysis (FBC, iron studies, TSAT, total
iron binding capacity (TIBC)). This way the site will
remain blinded to any change in Hb post randomisation.
Randomisation and blinding
Patients will be allocated to active treatment (FCM) or
placebo in a 1:1 ratio using minimisation (with a random
element incorporated) taking into account age (<70 years/
70+ years), baseline haemoglobin (<100/100+ g/L), centre
and type of operation (major, major-plus or complex).
Blinding
FCM solution is dark brown in appearance. Blinding will
be achieved by shielding the patients from seeing prepar-
ation of the study drug and having unblinded study
personnel not involved in any study assessments (effi-
cacy or safety) responsible for preparing and administer-
ing the study treatment. Preparing and administering the
study drug behind a screen or curtain will achieve this.
The drug will then be shielded from vision (Opabag (B
Braun, Melsungen, Germany)) light protection bags) and
administered through black tubing (Intrafix Air P with
black pipe (B Braun, Melsungen, Germany)).
Sample size and justification
The sample size requirement was calculated for the
composite primary endpoint of blood transfusion or
death by 30 days. The assumptions for the sample size
calculations were based on data from the pilot study and
observational trials and audits. The anticipated risk of
blood transfusion in the control group is approximately
40 %. Using a type-1 error rate of 5 % and allowing for a
5 % loss in follow-up, recruiting 500 patients (250 in
each group) will give 90 % power to detect an absolute
reduction in risk of 14 % (i.e. 35 % relative risk reduc-
tion, RR = 0.65) in the treatment group and it will give
approximately 80 % power to detect an absolute risk
reduction of 12 % (i.e. 30 % RR reduction)).
Discussion
The problem of anaemia in patients undergoing major
surgery is being increasingly recognised [4]. No major
clinical trial has been conducted to address the correction
of iron deficiency and anaemia by the use of parenteral
iron in patients undergoing major surgery. The NHS
Enhanced Recovery Partnership Programme (ERP) [27]
has highlighted the need to address anaemia in surgical
patients as a correctable condition, but no specific recom-
mendations or guidelines for the evaluation or treatment
of anaemia in these patients have been proposed.
PREVENTT is designed as a randomised, double-blind,
parallel-group, placebo-controlled, multi-centre study to
investigate the efficacy and safety of IV iron compared to
that of placebo in a patient population with anaemia under-
going major surgery. The dosing is based on the maximum
dose of IV FCM (Ferinject®, Vifor Pharma UK, Bagshot,
UK) that can be safely given in a reasonable time period.
As anaemia treatment is not standard care in these
patients it is deemed acceptable to use a placebo control
group for the supplemental IV iron therapy. The trial
methodology is based on the FAIR-HF trial [28]. In
recent trials in patients with chronic heart failure who
demonstrate iron deficiency with and without anaemia,
these were randomised to receive FCM or placebo for
6–12 months [13, 29].
The trial design is pragmatic and aims to include the
proposed intervention within current NHS timelines.
Standard practice is for patients to attend the surgical
pre-assessment clinic 10 days to 6 weeks prior to oper-
ation. This is the same time period required for IV iron
to produce an effective rise in Hb levels. Therefore,
anticipated surgery in 10 days to 6 weeks was defined in
the inclusion criteria.
The paradigm of patient blood management is becom-
ing increasingly accepted in order to reduce unnecessary
blood transfusions and to improve outcomes after sur-
gery. It is defined as the timely application of evidence-
based medical and surgical concepts designed to maintain
haemoglobin concentration, optimise haemostasis and
minimise blood loss in an effort to improve patient out-
come [30]. It consists of 3 pillars: 1) the optimisation of
erythropoiesis; 2) minimising blood loss and bleeding and
3) harnessing patient reserve and the tolerance of an-
aemia. The recognition and treatment of anaemia in the
preoperative period is key to the first pillar. This must be
integrated with other interventions, including preventing
coagulopathy and bleeding and increased usage of re-
strictive transfusion thresholds [31, 32], in a multimodal,
multidisciplinary approach to improve patient outcomes.
Trial status
The study opened to recruitment in September 2013
and is anticipated to close in August 2016.
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